Promote Corneal Healing with Opticyte Amniotic Ocular Matrix
Merakris Therapeutics ocular tissue technology is based on a sophisticated and delicate manufacturing process intended to retain extracellular matrix properties and structures. This makes it ideal for ocular applications.
-Processed without harsh chemical reagents that may cause irritation when placed in the corneal bed.
-Opticyte Matrix provides an ophthalmic barrier to the corneal surface and supports cell attachment and ingrowth.
-Minimal scarring is observed in Opticyte Matrix-protected corneas during healing and re-epithelialization.
Common indications:
H11.001 – H11.069 Pterygium of the eye
H11.811 – H11.813 Pseudopterygium
H16.001-H16.079 Corneal ulcer
H16.121-H16.123 Filamentary keratitis
H16.141-H16.143 Punctate keratitis
H16.221-H16.223 Keratoconjunctivitis sicca, not specified as Sjogren’s
H16.231-H16.239 Neurotrophic keratoconjunctivitis
H18.10-H18.13 Bullous keratopathy
H18.211-H18.213 Corneal edema secondary to contact lens
H18.40 – H18.49 Corneal degeneration
H18.821-H18.823 Corneal disorder due to contact lens
H18.831-H18.833 Recurrent corneal erosion
T86.841-T86.843 Corneal transplant
FDA approved and billable to most major medical insurances.
Procedure
Opticyte Ocular Matrix can be easily
applied to the ocular surface by:
• Absorbable sutures
• Biologic tissue adhesive
• Contact lenses
Safety & Quality
Opticyte Ocular Matrix is processed at
an FDA-registered and AATB-accredited
institution, providing clinicians a safe
and high-quality tissue product for use
in ophthalmic procedures.
Manufactured by Merakris Therapuetics
Opticyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1270 and 1271.
